Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S1434; text: CR S1433)
This Senate resolution designates February 27, 2025, as "Rare Disease Day" and formally recognizes the importance of improving awareness, encouraging early and accurate diagnosis, and supporting national and global research on rare diseases. The resolution cites statistics on rare disease prevalence, references the Orphan Drug Act and FDA/NIH programs, and is a non‑binding, symbolic statement of congressional recognition.
All support recognition, but differ on follow‑up funding and federal role
Simple commemorative resolution typically moves easily under suspension or unanimous consent, though requires House action to mirror Senate.
This Senate resolution designates February 27, 2025, as "Rare Disease Day" and formally recognizes the importance of improving awareness, encouraging early and accurate diagnosis, and supporting national and global research on rare diseases.
The resolution cites statistics on rare disease prevalence, references the Orphan Drug Act and FDA/NIH programs, and is a non‑binding, symbolic statement of congressional recognition.
This is a nonbinding Senate resolution designating a day; it does not create binding law and thus cannot 'become law' by itself.
How solid the drafting looks.
All support recognition, but differ on follow‑up funding and federal role
These are examples from the analysis, not a ranked list of the most-affected groups.
All support recognition, but differ on follow‑up funding and federal role
Likely strongly supportive as a humanitarian and public‑health affirmation that spotlights underserved patients and research needs.
Will welcome the recognition but note the resolution is symbolic and does not secure funding or guarantee access to treatments.
Generally favorable; sees the resolution as low‑cost, bipartisan recognition of a clear public‑health issue.
Will appreciate the non‑binding nature but will look for measurable next steps or accountability.
Likely supportive of the recognition and patient sympathy but cautious about expanding federal programs or subsidizing high‑cost therapies.
Prefers private‑sector innovation and oversight to prevent unintended costs.
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Still ahead
This is a nonbinding Senate resolution designating a day; it does not create binding law and thus cannot 'become law' by itself.
The bill has not accumulated any surfaced votes yet.
All support recognition, but differ on follow‑up funding and federal role
This is a nonbinding Senate resolution designating a day; it does not create binding law and thus cannot 'become law' by itself.
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for A resolution designating February 27, 2025, as "Rare Disease D…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.